Compass Therapeutics
2015
FOUNDED
PRIVATE
STATUS
51-60
EMPLOYEES
Series A
LATEST DEAL TYPE
$132M
LATEST DEAL AMOUNT
18
INVESTORS
Description
Operator of a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics. The company has broadly drugged the immune system by generating epitopically diverse antibody panels to more than 40 targets across all immune cell types and is leveraging its proprietary StitchMabsTM and common light-chain based multispecific platforms to empirically identify combinations and multispecifics with optimized activity.
Website
Formerly Known As
Kairos Biologics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Primary Office
- 245 First Street
- 3rd Floor
- Cambridge, MA 02142
- United States
+1 (617) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Compass Therapeutics’s full profile, request a free trial.
Compass Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series A) | 12-Jul-2018 | $132M | 00000 | Completed | Clinical Trials - Phase 1 | |
| 3. Accelerator/Incubator | 00000 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A2) | 06-Sep-2016 | $50M | $170M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC (Series A1) | 02-Jun-2015 | $120M | $120M | Completed | Clinical Trials - Phase 1 |
Compass Therapeutics Competitors (57)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sutro Biopharma | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| 0-0000 | Failed Transaction (M&A) | Vienna, Austria | 00 | 000.00 | 000000&0 | |
| 0000000 0000000000 | Formerly VC-backed | Heidelberg, Germany | 000 | 00000 | 00000000000 | 00000 |
| 0000000 00000000 | Formerly VC-backed | Bothell, WA | 0000 | 00000 | 000000000 | 00000 |
| 000000 00000000000 | Failed Transaction (M&A) | Cambridge, MA | 000 | 00000 | 000000&0 |
Compass Therapeutics Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Biomatics Capital | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| BioMed Realty | Real Estate | Minority | 000 0000 | 000000 0 | ||
| Alexandria Venture Investments | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Cowen Private Investments | Other | Minority | 000 0000 | 000000 0 | ||
| Polaris Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
Compass Therapeutics Executive Team (11)
5 Former Executives
You’re viewing 5 of 11 executives. Get the full list »Compass Therapeutics Board Members (11)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Ben Auspitz | F-Prime Capital Partners | Board Member | 000 0000 | |
| Bruce Steel | Self | Board Observer | 000 0000 | |
| Carl Gordon Ph.D | OrbiMed | Board Member | 000 0000 | |
| Julie Sunderland | Biomatics Capital | Board Member | 000 0000 | |
| Philip Ferneau JD | Borealis Ventures | Board Member | 000 0000 |
2 Former Board Members
You’re viewing 5 of 11 board members. Get the full list »